Abstract: Embodiments herein relate to the field of lysosomal storage disorders, and, more specifically, to methods of treating lysosomal storage disorders such as Niemann-Pick type C disease, for instance with inhibitors of histone deacetylases, particularly inhibitors of class 1 histone deacetylases. In various embodiments, methods of treating Niemann-Pick type C disease with inhibitors of class 1 histone deacetylases are described.

Abstract: Embodiments herein relate to histone deacetylaces (HDACs) and HDAC inhibitors, such as trichostatin A (TSA) and TSA analogues. Embodiments provide simple methods of synthesizing TSA and TSA analogues. These methods provide routes of synthesis of TSA and TSA analogues that enable the production of the HDAC inhibitors at lower cost and in greater quantities than previously were available.

Abstract: Embodiments herein relate to the field of lysosomal storage disorders, and, more specifically, to methods of treating lysosomal storage disorders such as Niemann-Pick type C disease, for instance with inhibitors of histone deacetylases, particularly inhibitors of class 1 histone deacetylases. In various embodiments, methods of treating Niemann-Pick type C disease with inhibitors of class 1 histone deacetylases are described.

Abstract: A process for preparing unsaturated esters useful as intermediates for HDAC inhibitors, by reacting an aldehyde or ketone having the following formula I: wherein R1 is an aromatic group or a combined aliphatic and aromatic group; X is —O—, —S—, —COO—, —OOC—, —CONR7—, or —R7NCO—; L1 an aliphatic linking group, an aromatic linking group, or a combined aliphatic and aromatic linking group; R2 and R3 are each independently hydrogen, a hydroxy group, an alkoxy group, an amino group, a carboxyl group, an amide group, an ester group, a carbamate group, an aliphatic group, an aromatic group, a combined aliphatic and aromatic group, R2 and R3 together are ?O, or one of R2 and R3 form a double bond with one of R4 and R5; R4 and R5 are each independently hydrogen, a hydroxy group, an alkoxy group, an amino group, a carboxy group, an amide group, an ester group, a carbamate group, an aliphatic group, an aromatic group, a combined aliphatic and aromatic group, or one of R4 and R5 form a double bond with one of R2 and

Abstract: Processes for preparing unsaturated esters useful as intermediates for HDAC inhibitors, by reacting an aldehyde or ketone with compounds having the following formula XX: wherein R8 is an aliphatic group, an aromatic group, or a combined aliphatic and aromatic group; R9 and R10 are each independently hydrogen, an aliphatic group, an aromatic group, a combined aliphatic and aromatic group, or R10 forms a double bond with L2 or X3; R11 and R12 are each independently an aliphatic group, an aromatic group, or a combined aliphatic and aromatic group; L2 is an aliphatic linking group, an aromatic linking group, or a combined aliphatic and aromatic linking group; A is P or As; L2 being selected so that the number of carbon atoms directly in the carbon chain between the R8 and R9 groups is at least 4, X1 and X2 are each independently O or a single bond, and X3 is O or forms R13 and double bond with R10, wherein R13 is an aliphatic group, an aromatic group, or a combined aliphatic and aromatic group.

Abstract: Process for preparing 1,10-phenanthroline ligands represented by the formula which comprises coupling a 1,10-phenanthroline of the formula with a ketone e.g. a dialkyl, cycloalkyl or bicycloalkyl ketone with a metal coupling reagent, preferably a lanthanide II e.g. samarium II, wherein R is hydrogen, alkyl, cycloalkyl, bicycloalkyl or aryl e.g. phenyl. The hydroxy group of the product may be converted to derivatives e.g. esters and ethers to form additional ligands. The hydroxy group of the product also may be converted to a reducible group e.g. the methoxy ether and the ether replaced by hydrogen in the reduction. The reduction product wherein R of the starting material is hydrogen can be coupled with a ketone in the process to provide 2,9-disubstituted 1,10-phenanthroline ligands. The ligands provided are preferably in chiral form and complex with metals, e.g. transition metals, which serve as catalysts in many processes such as addition and substitution reactions.

Abstract: Derivatized type A virginiamycins having a reactive functionalized side chain, and a process for making the virginiamycin derivatives. The side chain contains a thioether linkage and a reactive group, such as a carboxylate ester or free carboxylic acid group.